S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
Where Are The Markets Going Next? (Ad)pixel
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 3/27 - 3/31
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
Stocks are for suckers – try this instead (Ad)
UK travelers face hours-long waits for ferries to France
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
Where Are The Markets Going Next? (Ad)pixel
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 3/27 - 3/31
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
Stocks are for suckers – try this instead (Ad)
UK travelers face hours-long waits for ferries to France
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
Where Are The Markets Going Next? (Ad)pixel
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 3/27 - 3/31
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
Stocks are for suckers – try this instead (Ad)
UK travelers face hours-long waits for ferries to France
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
Where Are The Markets Going Next? (Ad)pixel
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 3/27 - 3/31
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
Stocks are for suckers – try this instead (Ad)
UK travelers face hours-long waits for ferries to France
Canada approves largest telecom deal in country's history
TSE:ONC

Oncolytics Biotech - ONC Stock Forecast, Price & News

C$1.65
+0.02 (+1.23%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
C$1.63
▼
C$1.68
50-Day Range
C$1.61
▼
C$2.53
52-Week Range
C$1.06
▼
C$3.10
Volume
18,091 shs
Average Volume
47,033 shs
Market Capitalization
C$103.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$6.00

Oncolytics Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
263.6% Upside
C$6.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of Oncolytics Biotech in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

See Top Rated MarketRank™ Stocks Here

ONC stock logo

About Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONC Stock News Headlines

March 29, 2023 | marketwatch.com
Oncolytic Virus Therapy Market Analysis by Global Report Research, 2028
March 29, 2023 | marketwatch.com
Oncolytics Biotech(R) to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium
April 1, 2023 | Vantage Point (Ad)
What To Do With Your Trades Today
There’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts pixel
March 28, 2023 | baystreet.ca
Oncolytics Biotech® Inc.
March 27, 2023 | finance.yahoo.com
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
March 14, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Oncolytics Biotech (ONCY)
March 10, 2023 | marketwatch.com
Oncolytic Virus Therapy Market Size, Assessment, Key Factors And Challenges By 2028
March 3, 2023 | msn.com
Earnings Scheduled For March 3, 2023
April 1, 2023 | Vantage Point (Ad)
What To Do With Your Trades Today
There’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts pixel
March 2, 2023 | msn.com
Oncolytics Biotech's Earnings: A Preview
February 21, 2023 | marketwatch.com
Oncolytic Virus Therapy Market Booming With Rising Demands and Massive Opportunities, 2023 - 2028
February 15, 2023 | marketwatch.com
Pancreatic Cancer Market Growth, Analysis, Industry Trends, Size, Shares and Forecast to 2028
February 9, 2023 | marketwatch.com
Global Oncolytic Virus Therapy Market 2023:Global Production, Value,Supply or Demand 2028 Forecasts
February 3, 2023 | markets.businessinsider.com
Maxim Group Reaffirms Their Buy Rating on Mesoblast (MESO)
February 2, 2023 | markets.businessinsider.com
Maxim Group Keeps Their Buy Rating on Blue Water Vaccines, Inc. (BWV)
January 31, 2023 | marketwatch.com
Oncolytic Virus Therapy Market Analysis by 2029 with Key Players Amgen, Oncolytics Biotech, Viralytics, Transgene SA
January 24, 2023 | markets.businessinsider.com
Maxim Group Reaffirms Their Buy Rating on NLS Pharmaceutics (NLSP)
January 24, 2023 | seekingalpha.com
ONCY Oncolytics Biotech Inc.
January 19, 2023 | markets.businessinsider.com
Maxim Group Reaffirms Their Buy Rating on Theriva Biologics (TOVX)
January 12, 2023 | marketwatch.com
Oncolytic Virus Market Future Trends Demand 2023, and Forecast to 2028
December 16, 2022 | finance.yahoo.com
Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?
November 29, 2022 | finance.yahoo.com
Is Olink Holding (OLK) Outperforming Other Medical Stocks This Year?
November 21, 2022 | finanznachrichten.de
Oncolytics Biotech Inc.: Oncolytics Biotech Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium
November 21, 2022 | finance.yahoo.com
Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium
November 18, 2022 | finance.yahoo.com
Oncolytics Biotech Inc. (ONCY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
November 15, 2022 | finanznachrichten.de
USA News Group: Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
November 15, 2022 | finanznachrichten.de
USA News Group: Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
See More Headlines
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONC Company Calendar

Today
3/31/2023
Next Earnings (Estimated)
5/04/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
TSE:ONC
CUSIP
N/A
CIK
N/A
Web
www.oncolyticsbiotech.com
Phone
+1-403-6707380
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$6.00
High Stock Price Forecast
C$9.00
Low Stock Price Forecast
C$3.00
Forecasted Upside/Downside
+263.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
C($0.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-24,840,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-79.34%
Return on Assets
-40.44%

Debt

Debt-to-Equity Ratio
1.41
Current Ratio
9.05
Quick Ratio
8.86

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.39 per share
Price / Cash Flow
4.22
Book Value
C$0.43 per share
Price / Book
3.84

Miscellaneous

Outstanding Shares
62,830,000
Free Float
N/A
Market Cap
C$103.67 million
Optionable
Not Optionable
Beta
1.76

Key Executives

  • Dr. Matthew C. Coffey M.B.A.
    Ph.D., Pres, CEO & Director
  • Mr. Kirk J. Look C.A.
    CA, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro (Age 55)
    Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc
    Comp: $558.94k
  • Dr. Thomas C. Heineman M.D.
    Ph.D., Chief Medical Officer
  • Ms. Allison Hagerman P.Eng.
    P.M.P., VP of Product Devel.
  • Jon Patton
    Director of Investor Relations & Communication
  • Dr. Grey Wilkinson Ph.D.
    Scientist of Translational Medicine
  • Mr. John Mark Lievonen F.C.A.
    FCA, Consultant
  • Dr. Daniel Douglas Von Hoff F.A.C.P. (Age 74)
    FACP, M.D., Consultant

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













ONC Stock - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONC shares.
View ONC analyst ratings or view top-rated stocks.

What is Oncolytics Biotech's stock price forecast for 2023?

4 brokers have issued 1 year price objectives for Oncolytics Biotech's shares. Their ONC share price forecasts range from C$3.00 to C$9.00. On average, they predict the company's share price to reach C$6.00 in the next twelve months. This suggests a possible upside of 263.6% from the stock's current price.
View analysts price targets for ONC or view top-rated stocks among Wall Street analysts.

How have ONC shares performed in 2023?

Oncolytics Biotech's stock was trading at C$2.22 at the beginning of 2023. Since then, ONC shares have decreased by 25.7% and is now trading at C$1.65.
View the best growth stocks for 2023 here.

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ONC earnings forecast.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR).

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

How do I buy shares of Oncolytics Biotech?

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Oncolytics Biotech's stock price today?

One share of ONC stock can currently be purchased for approximately C$1.65.

How much money does Oncolytics Biotech make?

Oncolytics Biotech (TSE:ONC) has a market capitalization of C$103.67 million. The company earns C$-24,840,000.00 in net income (profit) each year or C($0.40) on an earnings per share basis.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The official website for the company is www.oncolyticsbiotech.com. The company can be reached via phone at +1-403-6707380.

This page (TSE:ONC) was last updated on 4/1/2023 by MarketBeat.com Staff